Baricitinib for COVID-19: a suitable treatment?
- PMID: 32251638
- PMCID: PMC7270794
- DOI: 10.1016/S1473-3099(20)30262-0
Baricitinib for COVID-19: a suitable treatment?
Comment in
-
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3. Lancet Infect Dis. 2020. PMID: 32251639 Free PMC article. No abstract available.
Comment on
-
COVID-19: combining antiviral and anti-inflammatory treatments.Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. Lancet Infect Dis. 2020. PMID: 32113509 Free PMC article. No abstract available.
References
-
- Smolen JS, Genovese MC, Takeuchi T. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46:7–18. - PubMed